What one share of Prime Medicine holds
We are a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression.
Prime Medicine’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.09 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.91 |
| Cash and investments | $0.26 |
| Book value | $0.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $1.97 | −$1.92 | $0.24 | −$2.34 | — | $0.89 |
| 2021 | $0.00 | −$14.19 | $0.32 | −$2.95 | — | — |
| 2022 | $0.00 | −$4.19 | $0.47 | −$4.36 | — | — |
| 2023 | $0.00 | −$2.18 | $0.10 | −$1.91 | — | $1.37 |
| 2024 | $0.03 | −$1.65 | $0.06 | −$1.10 | — | $1.17 |
| 2025 | $0.03 | −$1.35 | $0.03 | −$1.12 | — | $0.67 |
Common questions about Prime Medicine
How much does one share of Prime Medicine earn?
Over the last 12 months, Prime Medicine lost $1.09 for each share.
Does Prime Medicine pay a dividend?
Prime Medicine didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Prime Medicine’s book value per share?
Prime Medicine’s book value is $0.22 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Prime Medicine have?
Each share of Prime Medicine has $0.26 of cash and investments, as of June 30, 2026.
What is Prime Medicine’s free cash flow per share?
−$0.91 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Prime Medicine bought back shares?
Prime Medicine’s share count rose about 5535% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.